Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes
Phase 3 study to examine whether treatment with ITCA-650 60 mcg/day or 40 mcg/day is superior to placebo when added to current therapy in reducing HbA1c in patients with type 2 diabetes.
Inclusion Criteria:
Exclusion Criteria:
Metaire, Louisiana 70006, United States
Metarie, Louisiana 70006, United States
Moorehead City, North Carolina 28557, United States
Carrolton, Texas 75007, United States
Corpus Cristi, Texas 78414, United States